Pharmacogenomics utilization as a tool for deprescribing in Veterans at high-risk for polypharmacy.

IF 1.6 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2026-08-01 Epub Date: 2026-10-01 DOI:10.1080/14622416.2026.2738672

Lauren Collier Murray, Erica Farina, Lauren Welch, Trisha Seys Ranola, Jennifer Piccolo

{"title":"Pharmacogenomics utilization as a tool for deprescribing in Veterans at high-risk for polypharmacy.","authors":"Lauren Collier Murray, Erica Farina, Lauren Welch, Trisha Seys Ranola, Jennifer Piccolo","doi":"10.1080/14622416.2026.2738672","DOIUrl":null,"url":null,"abstract":"Background: Pharmacogenomics (PGx) assesses how genetic variation influences medication response and can support medication optimization. For patients with substantial medication burden, optimization efforts are essential for improving medication safety. At the Madison VA, Veterans identified through a polypharmacy dashboard receive comprehensive medication reviews to determine opportunities for deprescribing. This quality improvement pilot evaluates the impact of incorporating PGx-guided recommendations into these deprescribing focused reviews.Methods: Veterans at a community‑based ambulatory care clinic identified via the polypharmacy dashboard were included in this pilot if they were taking at least two PGx-impacted medications based on the standard 22-gene panel available within the Veterans Health Administration. PGx Clinical Pharmacist Practitioners (CPPs) consented Veterans for PGx testing, conducted chart reviews, and completed telehealth visits to deprescribe medications based on PGx results if appropriate.Results: Fifty-eight patients met criteria and 50 completed PGx testing. After exclusions, 44 patients were analyzed. Deprescribing recommendations were made for 75% (33/44) of patients, resulting in 15 PGx-guided deprescribing interventions.Conclusion: Incorporating PGx into existing workflows enhances medication optimization and supports deprescribing for Veterans at high risk of polypharmacy.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"387-394"},"PeriodicalIF":1.6000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671460/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2026.2738672","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pharmacogenomics (PGx) assesses how genetic variation influences medication response and can support medication optimization. For patients with substantial medication burden, optimization efforts are essential for improving medication safety. At the Madison VA, Veterans identified through a polypharmacy dashboard receive comprehensive medication reviews to determine opportunities for deprescribing. This quality improvement pilot evaluates the impact of incorporating PGx-guided recommendations into these deprescribing focused reviews.

Methods: Veterans at a community‑based ambulatory care clinic identified via the polypharmacy dashboard were included in this pilot if they were taking at least two PGx-impacted medications based on the standard 22-gene panel available within the Veterans Health Administration. PGx Clinical Pharmacist Practitioners (CPPs) consented Veterans for PGx testing, conducted chart reviews, and completed telehealth visits to deprescribe medications based on PGx results if appropriate.

Results: Fifty-eight patients met criteria and 50 completed PGx testing. After exclusions, 44 patients were analyzed. Deprescribing recommendations were made for 75% (33/44) of patients, resulting in 15 PGx-guided deprescribing interventions.

Conclusion: Incorporating PGx into existing workflows enhances medication optimization and supports deprescribing for Veterans at high risk of polypharmacy.

查看原文本刊更多论文

药物基因组学在退伍军人多重用药高风险人群中的应用。

背景：药物基因组学（PGx）评估遗传变异如何影响药物反应，并可以支持药物优化。对于用药负担较大的患者，优化工作对于提高用药安全至关重要。在麦迪逊退伍军人管理局，通过综合药房仪表板识别的退伍军人会收到全面的药物评估，以确定减少处方的机会。这个质量改进试点评估将pgx指导的建议纳入这些描述重点审查的影响。方法：根据退伍军人健康管理局（Veterans Health Administration）提供的标准22基因面板，如果在社区门诊诊所接受治疗的退伍军人正在服用至少两种影响pgx的药物，则通过综合用药仪表板识别他们，并将其纳入该试点。PGx临床药师（CPPs）同意退伍军人进行PGx测试，进行图表审查，并完成远程医疗访问，根据PGx结果酌情开药。结果：58例患者符合标准，50例完成PGx检测。排除后，对44例患者进行分析。对75%（33/44）的患者提出减处方建议，产生15种pgx指导的减处方干预措施。结论：将PGx纳入现有工作流程可以优化药物使用，支持高风险退伍军人的处方处方。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.